AMP Horizons Series: Recommendations for Clinical CYP2D6 Genotyping Allele Selection

A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy


AMP Pharmacogenomics Working Group members Dr. Andria del Tredici moderates as Dr. Ann Moyer provides an update on clinical CYP2D6 testing, which was recently published online by the JMD. With a goal of promoting standardization of clinical PGx testing across different clinical laboratories, this Working Group has published recommendations on CYP2C19, CYP2C9 and Warfarin allele selections previously, and now the CYP2D6 genotyping allele selection for clinical laboratories to use as guidelines when designing and developing these PGx assays. Healthcare providers may also find these documents useful in comparing and contrasting PGx tests across clinical laboratories when they are familiar with a “must-test” list for each of the pharmacogenes.

Learning Objectives:

  • Review CYP2D6 pharmacogenetics (PGx) and highlight the importance of standardization of clinical PGx and its implications to patient care
  • Review the AMP PGx Working Group ‘Tier’ system of PGx sequence variants/alleles recommendation
  • Explain the key attributes of Tier 1 and Tier 2 recommended alleles for CYP2D6 genotyping

Practice Guideline Available Here

Picture of Speaker Ann Moyer
 Picture of Moderator, Andria del Tredici
Ann Moyer, MD, PhD
Mayo Clinic
Rochester, MN
Andria del Tredici, PhD
Acadia Pharmaceuticals
San Diego, CA

 1 hr
Level of Instruction: Basic
Date Recorded: June 15, 2021

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to purchase course and claim credit: March 20, 2024

Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.